US Stock Market Movement: Arcus Biosciences plummets on October 21: rating downgrade, forecasted loss, and rebound reversal

Arcus Biosciences October 21st Significant Drop Interpretation

Keywords: Rating downgrade, expected loss, rebound retracement

1. On October 21st, Morgan Stanley downgraded Arcus to "hold", maintaining a target price of $23; on the same day, Citibank raised its target price, and Wedbush also raised its target price, with analysts holding differing views.

2. The quarterly earnings forecast released on October 20th shows the company may record a loss of $0.92 per share, with revenue down 54.3% year-on-year; on October 21st, the stock price rose 7.27% due to ARC-20 data, but saw a significant decline the following day, possibly retracing the previous trading day's gains.

(Disclaimer: This content is generated by AI technology based on publicly available information, provided for reference only and does not constitute investment advice.)